Table 2.

Trials utilizing MRD to guide initial and maintenance therapy.

Study	Primary endpoint	Population	Treatment administered	Based on
1. MRD testing utilizing NGF (10-5)
RADAR	PFS	Standard risk patients after auto SCT	Randomization to arms including R maint, RVd consolidation + R maint, R-isa maint, or isa-RVd consolidation + R isa maint	Patients who received Isa main were MRD -ve after initial treatment. The remaining tested +ve.
REMNANT	PFS	MRD -ve patients randomized to two arms	Dara-Kd	Patients who received Dara-Kd tested MRD +ve vs those who were only continuously observed every 4 months
NCT04221178	MRD -ve at one year	Patients on 3 years of continuous maint	Maint treatment	None of the patients tested MRD +ve
PREDATOR	EFS	Patients after 1-2 prior lines of therapy who are MRD negative	Dara vs. observation	Patients who were on Dara tested MRD+ve while those on observation were MRD-ve
2. MRD testing utilizing NGS
NCT04140162	MRD	Patients who got induction with dara-R	Following induction, received either consolidation with dara-RVd vs. maint dara	Patients on dara-RVd tested +ve vs.-ve for those who received maint dara
AURGIA*	MRD	Patients who got auto-SCT	Patients received DARA-R vs R only.	Patients on DARA-R only tested MRD+ve.
MASTER*	MRD	Patients who received dara-KRd	Additional dara_KRd vs. observation after achieved MRD-ve twice	Patients receiving additional dara-KRd were those who tested MRD+ve.

EFS, event-free survival.

*denotes (10^-5).